Blue Trust Inc. Purchases 2,351 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Blue Trust Inc. grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 143.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,989 shares of the company’s stock after buying an additional 2,351 shares during the quarter. Blue Trust Inc.’s holdings in Vir Biotechnology were worth $30,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. nVerses Capital LLC bought a new position in Vir Biotechnology in the third quarter valued at approximately $56,000. Vontobel Holding Ltd. boosted its holdings in shares of Vir Biotechnology by 27.8% in the 3rd quarter. Vontobel Holding Ltd. now owns 57,446 shares of the company’s stock valued at $430,000 after purchasing an additional 12,511 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. increased its stake in shares of Vir Biotechnology by 491.7% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 18,959 shares of the company’s stock valued at $169,000 after purchasing an additional 15,755 shares during the last quarter. Algert Global LLC acquired a new position in shares of Vir Biotechnology during the 2nd quarter worth $1,485,000. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of Vir Biotechnology during the 2nd quarter worth $135,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Stock Up 23.6 %

Shares of VIR stock opened at $9.26 on Friday. The firm has a market capitalization of $1.27 billion, a P/E ratio of -2.36 and a beta of 0.46. Vir Biotechnology, Inc. has a twelve month low of $7.12 and a twelve month high of $13.09. The stock’s fifty day simple moving average is $7.75 and its 200 day simple moving average is $8.87.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($0.96) by ($0.60). The firm had revenue of $2.38 million for the quarter, compared to the consensus estimate of $5.54 million. Vir Biotechnology had a negative return on equity of 35.00% and a negative net margin of 678.40%. The business’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same quarter last year, the firm posted ($1.22) earnings per share. As a group, equities research analysts expect that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on VIR shares. Barclays lifted their target price on Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research report on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Tuesday, August 20th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Vir Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $36.80.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction on Monday, September 9th. The shares were sold at an average price of $7.80, for a total transaction of $95,082.00. Following the transaction, the director now owns 11,616 shares in the company, valued at approximately $90,604.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).